The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Melatonin Ameliorates the Progression of Atherosclerosis via Mitophagy Activation and NLRP3 Inflammasome Inhibition
Open accessAbstract
The NLRP3 (nucleotide‐binding domain and leucine‐rich repeat pyrin domain containing 3) inflammasome‐mediated inflammatory responses are critically involved in the progression of atherosclerosis (AS), which is the essential cause for cardiovascular diseases. Melatonin has anti‐inflammatory properties. However, little is known about the potential effects of melatonin in the pathological process of AS. Herein, we demonstrate that melatonin suppressed prolonged NLRP3 inflammasome activation in atherosclerotic lesions by reactive oxygen species (ROS) scavenging via mitophagy in macrophages. The atherosclerotic mouse model was induced with a high‐fat diet using ApoE−/− mice. Melatonin treatment markedly attenuated AS plaque size and vulnerability. Furthermore, melatonin decreased NLRP3 inflammasome activation and the consequent IL‐1 β secretion within atherosclerotic lesions. Despite the unchanged protein expression, the silent information regulator 3 (Sirt3) activity was elevated in the atherosclerotic lesions in melatonin‐treated mice. In ox‐LDL‐treated macrophages, melatonin attenuated the NLRP3 inflammasome activation and the inflammatory factors secretion, while this protective effect was abolished by either Sirt3 silence or autophagy inhibitor 3‐MA. Mitochondrial ROS (mitoROS), which was a recognized inducer for NLRP3 inflammasome, was attenuated by melatonin through the induction of mitophagy. Both Sirt3‐siRNA and autophagy inhibitor 3‐MA partially abolished the beneficial effects of melatonin on mitoROS clearance and NLRP3 inflammasome activation, indicating the crucial role of Sirt3‐mediated mitophagy. Furthermore, we demonstrated that melatonin protected against AS via the Sirt3/FOXO3a/Parkin signaling pathway. In conclusion, the current study demonstrated that melatonin prevented atherosclerotic progression, at least in part, via inducing mitophagy and attenuating NLRP3 inflammasome activation, which was mediated by the Sirt3/FOXO3a/Parkin signaling pathway. Collectively, our study provides insight into melatonin as a new target for therapeutic intervention for AS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773 · cited 1×
“Also, AS has been identified as a chronic inflammatory disease, in which inflammation is a primary driving force for lesion rupture [1].”
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Melatonin as a mitochondria-targeted antioxidant: one of evolution's best ideas
Reiter, R. J., Rosales-Corral, S., Tan, D. X., Jou, M. J., Galano, A., & Xu, B. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2609-7 · Cited by 558
Mitochondria: diversity in the regulation of the NLRP3 inflammasome
Gurung, P., Lukens, J. R., & Kanneganti, T.-D. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.11.008 · Cited by 393
Huang, L.-S., Cobessi, D., Tung, E. Y., & Berry, E. A. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.05.053 · Cited by 304 · cited 1×
“A previous research showed that mtROS overproduction by the inhibition of mitochondrial complex I or complex III triggered NLRP3 inflammasome activation [38, 39].”
Mohammadi-Sartang, M., Ghorbani, M., & Mazloom, Z. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2017.11.003 · Cited by 94
Cited by
Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances
Xu, X., Pang, Y., & Fan, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02253-4 · Cited by 800
Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target
Zhang, J., Xiang, H., Liu, J., Chen, Y., He, R.-R., & Liu, B. (2020) · Theranostics · doi:10.7150/thno.45922 · Cited by 503
Mitochondrial autophagy: molecular mechanisms and implications for cardiovascular disease
Li, A., Gao, M., Liu, B., Qin, Y., chen, L., Liu, H., Wu, H., & Gong, G. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04906-6 · Cited by 456
Mitophagy in cardiovascular diseases: molecular mechanisms, pathogenesis, and treatment
Ajoolabady, A., Chiong, M., Lavandero, S., Klionsky, D. J., & Ren, J. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.06.007 · Cited by 258
Self-citationMishra, S. R., Mahapatra, K. K., Behera, B. P., Patra, S., Bhol, C. S., Panigrahi, D. P., Praharaj, P. P., Singh, A., Patil, S., Dhiman, R., et al. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106013 · Cited by 195
Mitochondria: the birth place, battle ground and the site of melatonin metabolism in cells
Tan, D.-X., & Reiter, R. J. (2019) · Melatonin Research · doi:10.32794/mr11250011 · Cited by 172
“reports documented the inhibitory action of melatonin on mitophagy (157) and others report that melatonin promotes mitophagy depending on the study conditions and experimental models (84, 158, 159).”
BackgroundTang, M., Liu, T., Jiang, P., & Dang, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105586 · Cited by 88
Metadata
- Authors
- Ma, S., Chen, J., Feng, J., Zhang, R., Fan, M., Han, D., Li, X., Li, C., Ren, J., Wang, Y., & Cao, F.
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 2018
- Issue
- 1
- Pages
- 9286458-9286458
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- OpenAlex
- W2891015697
- Cited by
- 241
- References
- 7
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.